Dr. Cesar Rodriguez, Icahn School of Medicine at Mount Sinai, United States
Dr. Cesar Rodriguez is a distinguished hematologist-oncologist specializing in multiple myeloma. He currently serves as Associate Professor of Medicine and Clinical Director for Multiple Myeloma at the Icahn School of Medicine at Mount Sinai, while also holding adjunct and leadership roles at Wake Forest University. With a medical degree from ITESM in Mexico and advanced training at Texas Tech, University of Louisville, and Harvard Medical School, Dr. Rodriguez has led numerous clinical trials and translational research projects focusing on immunotherapy, 3D tumor organoids, and personalized medicine. He is the CEO of Immunohub, an educational portal on immunotherapy-related toxicities, and serves on multiple international review committees. Dr. Rodriguez has been recognized with honors such as the Cure Multiple Myeloma Heroes Award (2022) and LLS Man of the Year (2014). He is a consultant for major pharmaceutical companies and an advocate for health equity across Latin America.
Publication Profile
Scopus
Educational Background
Dr. Cesar Rodriguez has cultivated an impressive educational foundation, beginning with his Medical Doctorate from Escuela de Medicina Ignacio A. Santos at the Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico (1997–2003). Early in his career, he completed a research program in immunology at Harvard Medical School (2000). He later pursued an Internal Medicine Residency at Texas Tech University Health Sciences Center in El Paso (2006–2009), followed by a competitive fellowship in Hematology and Oncology at the University of Louisville (2009–2012). He gained specialized bone marrow transplant experience as a Visiting Resident at Massachusetts General Hospital (2007), and as a Visiting Fellow at both the Seattle Cancer Care Alliance and Memorial Sloan Kettering Cancer Center in 2011. Further enhancing his oncology expertise, Dr. Rodriguez completed the prestigious High Impact Cancer Research Program in Cancer Biology and Therapeutics at Harvard Medical School (2018–2019), solidifying his credentials as a leading figure in cancer research and clinical hematology.
Honors and Awards
Dr. Cesar Rodriguez has received numerous prestigious honors that reflect his outstanding contributions to clinical research, patient care, and community impact. In 2017, he was awarded First Place in the Junior Faculty Category during the Internal Medicine Research Day at Wake Forest School of Medicine, recognizing his early academic excellence. He was also named one of Louisville’s Top 40 Under 40 in 2015 by Business Insider, highlighting his leadership and innovation. Further acknowledging his service, he was commissioned as a Kentucky Colonel by Governor Steven Beshear, the highest honor bestowed by the Commonwealth of Kentucky. In 2014, he received both the Leukemia and Lymphoma Society’s Man of the Year Award and the National Patient’s Choice Award, celebrating his dedication to hematologic care and patient advocacy. Most recently, in 2022, he was honored with the Multiple Myeloma Health Equity Award by Cure Multiple Myeloma Heroes, emphasizing his commitment to equity in cancer treatment.
Research Focus
Dr. Cesar Rodriguez’s research is primarily focused on multiple myeloma and related plasma cell dyscrasias, with a strong emphasis on immunotherapy, minimal residual disease (MRD) monitoring, and CAR-T cell therapy. His scholarly contributions include work on sequencing immunotherapy in multiple myeloma, MRD-negative status as a predictor of long-term progression-free survival, and the implications of delayed neutrophil recovery in CAR-T–treated patients. These studies, often published in high-impact, open-access journals, demonstrate his dedication to improving clinical outcomes through real-world evidence and translational science. Dr. Rodriguez also engages in patient-centered research, such as publishing plain-language summaries to increase accessibility of clinical trial results. As a member of international committees like the International Myeloma Working Group and the European Hematology Association, he collaborates on setting treatment standards and evaluating cutting-edge therapies. His research agenda bridges clinical care with innovation, contributing significantly to the evolving landscape of hematologic oncology.
Publication Top Notes
-
Endotelial morphometric findings in cataract surgery: Comparative study between extracapsular and intracapsular, 2000
-
A clinical approach to solving discrepancies in therapeutic drug monitoring results for patients on sirolimus or tacrolimus, 2015, Cited by: 56
-
Novel evidence that pituitary gonadotropins directly stimulate human leukemic cells, 2015, Cited by: 45
-
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem cell transplant for multiple myeloma, 2017, Cited by: 198
-
ASBMT Practice Guidelines Committee Survey on Long Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors, 2018, Cited by: 41
-
KLF9-dependent ROS regulate melanoma progression in stage-specific manner, 2019, Cited by: 79
-
Paraproteinemia and serum protein electrophoresis interpretation, 2019, Cited by: 6
-
Special consideration for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction, 2019, Cited by: 23
-
Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN, 2020, Cited by: 311
-
Bone health management after hematopoietic cell transplantation: An expert panel opinion, 2020, Cited by: 58